Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,837.66
    +425.05 (+0.83%)
     

  • CMC Crypto 200

    1,334.09
    +21.47 (+1.59%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,407.00
    +9.00 (+0.38%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

AstraZeneca heart drug in regulatory fast lane for wider use

Reuters - UK Focus

LONDON, April 29 (Reuters) - U.S. regulators are to fast-track the review of a new use of AstraZeneca (NYSE: AZN - news) 's heart drug Brilinta, meaning it could get the green light in the third quarter to be given to patients with a history of heart attacks.

The drugmaker said on Wednesday the decision by the Food and Drug Administration (FDA) reflected the potential of Brilinta to address an unmet medical need by reducing risks for patients who had a heart attack one to three years previously.

The FDA grants a priority review when a medicine has scope to provide significant improvements in the treatment.

AstraZeneca is relying on Brilinta, which it believes can sell $3.5 billion annually by 2023, to help offset a wave of patent losses on older drugs. The product was a central plank in its defence against a takeover bid by Pfizer (NYSE: PFE - news) last year. (Reporting by Ben Hirschler; editing by David Clarke)